Stockscreener 앱 받기
1.08
2.86%
0.03
전일 마감가:
$1.05
열려 있는:
$1.07
하루 거래량:
154.68K
Relative Volume:
0.58
시가총액:
$2.20M
수익:
-
순이익/손실:
$-9.82M
주가수익비율:
-0.1347
EPS:
-8.02
순현금흐름:
$-7.75M
1주 성능:
-0.92%
1개월 성능:
-6.90%
6개월 성능:
-54.81%
1년 성능:
-89.09%
1일 변동 폭
$1.0604
$1.1473
1주일 범위
$1.00
$1.1473
52주 변동 폭
$1.00
$13.35
Dermata Therapeutics Inc Stock (DRMA) Company Profile
명칭
Dermata Therapeutics Inc
전화
(858)-223-0882
주소
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
DRMA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
1.08 | 2.20M | 0 | -9.82M | -7.75M | -27.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Dermata Therapeutics Inc 주식(DRMA)의 최신 뉴스
Dermata Therapeutics, Inc. Receives Approval from FDA for the Proprietary Name Xyngarifor for Its Phase 3 Clinical Drug Candidate in Acne - Marketscreener.com
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM) - AccessWire
Dermata's Acne Treatment 'Xyngari' Secures FDA Name Approval; Phase 3 Data Expected March 2025 - StockTitan
Dermata Therapeutics stock hits 52-week low at $1.05 By Investing.com - Investing.com UK
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne - AccessWire
Dermata Secures Key Patent for Revolutionary Acne Treatment DMT310 Ahead of Phase 3 Results - StockTitan
DRMAWDermata Therapeutics, Inc. Warrant Latest Stock News & Market Updates - StockTitan
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne - AccessWire
Dermata Therapeutics, Inc. Completes Enrollment in First Pivotal DMT310 Phase 3 Star-1 Clinical Trial for Acne - Marketscreener.com
Dermata Completes Phase 3 Trial Enrollment for Novel Weekly Acne Treatment - StockTitan
ARMISTICE CAPITAL, LLC Increases Stake in Dermata Therapeutics I - GuruFocus.com
Dermata Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Dermata Therapeutics stock hits 52-week low at $1.2 amid steep decline - Investing.com UK
Earnings Flash (DRMA) DERMATA THERAPEUTICS Reports Q3 Loss $-2.04 - Marketscreener.com
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - AccessWire
Dermata Hits 50% Enrollment in Phase 3 Acne Trial, Raises $7.8M in 2024 | DRMAW Stock News - StockTitan
Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024 - The Manila Times
Dermata stock hits 52-week low at $1.22 amid market challenges - Investing.com Australia
Sponge Power: Dermata's Revolutionary Acne Treatment Trial Results Due In 2025 - RTTNews
Analyzing DRMA’s price-to-book ratio for the last quarter - US Post News
Dermata stock hits 52-week low at $1.28 amid market challenges - Investing.com UK
Acne Vulgaris Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2024-2034), States DelveInsight | Clinuvel Pharma, Novan, Dermata Therapeutics, ioPharmX, Bausch Health - Barchart
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024 - AccessWire
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.2% - Defense World
How does Dianthus Therapeutics Inc (DNTH) change from a tortoise to a hare? - SETE News
Ameritas Investment Partners Inc. Has $1.82 Million Stake in Dolby Laboratories, Inc. (NYSE:DLB) - Defense World
How to interpret Design Therapeutics Inc (DSGN)’s stock chart patterns - US Post News
The Dixie Group (NASDAQ:DXYN) Earns Hold Rating from Analysts at StockNews.com - Defense World
Darden Restaurants, Inc. (NYSE:DRI) Holdings Raised by XTX Topco Ltd - Defense World
Darden shares steady on neutral rating from Piper Sandler - Investing.com India
Darden stock 'ready to run' with delivery boost and sales initiativesBTIG By Investing.com - Investing.com South Africa
Ensysce Biosciences (NASDAQ:ENSC) Stock Quotes, Forecast and News Summary - Benzinga
Argent Trust Co Has $533,000 Stock Position in Darden Restaurants, Inc. (NYSE:DRI) - Defense World
Diamondback Energy 12.77M share Spot Secondary priced at $178.00 - TipRanks
Darden price target raised to $195 from $185 at Truist - TipRanks
Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 7.5% - MarketBeat
Analytical Overview: Dermata Therapeutics Inc (DRMA)’s Ratios Tell a Financial Story - The Dwinnex
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - Kilgore News Herald
A Look at Dermata Therapeutics Inc (DRMA) Shares in the Recent Past Indicates Growth - SETE News
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - StockTitan
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - StockTitan
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Benzinga
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September - Benzinga
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket - Benzinga
Entero Therapeutics (NASDAQ:ENTO) Stock Quotes, Forecast and News Summary - Benzinga
Acne Vulgaris Market Size is Set for Rapid Growth as Innovative - openPR
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 - StockTitan
Prepare Yourself for Liftoff: Dermata Therapeutics Inc (DRMA) - SETE News
Can you now get a good deal on Dermata Therapeutics Inc’s shares? - US Post News
Daily Market Movement: Dermata Therapeutics Inc (DRMA) Sees a 1.16 Increase, Closing at 1.74 - The Dwinnex
Axillary Hyperhidrosis Market Expected to Experience Major - openPR
Dermata Therapeutics Inc (DRMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):